American Journal of Ophthalmology
Volume 146, Issue 2 , Pages 159-171 , August 2008

Debunking Myths in Physician–Industry Conflicts of Interest

  • Paul R. Lichter

      Affiliations

    • Corresponding Author InformationInquiries to Paul R. Lichter, Department of Ophthalmology and Visual Sciences, University of Michigan, W. K. Kellogg Eye Center, 1000 Wall Street, Ann Arbor, Michigan 48105

,Accepted 2 April 2008.

References 

  1. Spingarn RW, Berlin JA, Strom BL. When pharmaceutical manufacturers' employees present grand rounds, what do residents remember?. Acad Med. 1996;71:86–88
  2. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift?. JAMA. 2000;283:373–380
  3. Chimonas S, Brennan TA, Rothman DJ. Physicians and drug representatives: exploring the dynamics of the relationship. J Gen Intern Med. 2007;22:184–190
  4. Campbell EG, Weissman JS, Ehringhaus S, et al. Institutional academic industry relationships. JAMA. 2007;298:1779–1786
  5. Cohen JJ, Cruess S, Davidson C. Alliance between society and medicine: the public's stake in medical professionalism. JAMA. 2007;298:670–673
  6. Coleman DL, Kazdin AE, Miller LA, Morrow JS, Udelsman R. Guidelines for interactions between clinical faculty and the pharmaceutical industry: one medical school's approach. Acad Med. 2006;81:154–160
  7. Richter R. New policy limits drug industry access (Stanford Report, September 12, 2006). http://med.stanford.edu/news_releases/2006/september/coi.htmlAccessed: April 1, 2008
  8. Wasserstein A, Brennan PJ, Rubenstein AH. Institutional leadership and faculty response: fostering professionalism at the University of Pennsylvania School of Medicine. Acad Med. 2007;82:1049–1056
  9. Merriam-Webster. “bribe.” Merriam-Webster Online Dictionary. http://aolsvc.merriam-webster.aol.com/dictionary/bribeAccessed: April 1, 2008
  10. Mansfield P. Bribes for doctors: a gift for bioethicists?. Am J Bioeth. 2003;3:47–48
  11. Wall LL, Brown D. The high cost of free lunch. Obstet Gynecol. 2007;110:169–173
  12. Harris G. Senators to push for registry of drug makers' gifts to doctors. New York Times, June 28, 2007:A16.
  13. U.S. Senate Special Committee on Aging. Paid to prescribe?: exploring the relationship between doctors and the drug industry, 2007. http://www.aging.senate.gov/hearing_detail.cfm?id=277848&Accessed: April 1, 2008
  14. Office of the Inspector General. OIG compliance program guidance for pharmaceutical manufacturers. Federal Register, 2003:23731–23743. http://oig.hhs.gov/authorities/docs/03/050503FRCPGPharmac.pdfAccessed: April 1, 2008
  15. Harris G. In article, doctors back ban on gifts from drug makers. New York Times, January 25, 2006:A14.
  16. Leary W. Doctors given millions by drug companies. New York Times, December 12, 1990:B13.
  17. Abelson R. Charities tied to doctors get drug industry gifts. New York Times, June 28, 2006:A1.
  18. Is your doctor tied to drug makers? [editorial] New York Times, July 2, 2007:A18.
  19. Elliott C. The drug pushers. Atlantic Monthly. 2006;297:82–93
  20. Carlat D. Dr. ‘drug rep.’ New York Times Magazine, November 25, 2007:64–69.
  21. Hensley S. Remedial lessons: when doctors go to class, industry often foots the bill—lectures tend to feature pills made by course sponsors; companies deny influence—a purple heartburn brochure. Wall Street Journal, December 4, 2002:A1.
  22. Hensley S, Martinez B. To sell their drugs, companies increasingly rely on doctors. Wall Street Journal (East Ed), July 15, 2005:A1,A2.
  23. Basler B. Ties that bind. AARP Bulletin Online 2008. http://www.aarp.org/bulletin/yourhealth/drug_rep_ties_that_bind.htmlAccessed: April 1, 2008
  24. Kassirer J. On the take: how medicine's complicity with big business can endanger your health. New York, New York: Oxford University Press; 2005;
  25. Angell M. The truth about the drug companies: how they deceive us and what to do about it. New York, New York: Random House, 2004.
  26. Brody H. Hooked: ethics, the medical profession, and the pharmaceutical industry. New York, New York: Rowan & Littlefield; 2007;
  27. Zipkin DA, Steinman MA. Interactions between pharmaceutical representatives and doctors in training (A thematic review). J Gen Intern Med. 2005;20:777–786
  28. Watson PY, Khandelwal AK, Musial JL, Buckley JD. Resident and faculty perceptions of conflict of interest in medical education. J Gen Intern Med. 2005;20:357–359
  29. Agrawal S, Saluja I, Kaczorowski J. A prospective before-and-after trial of an educational intervention about pharmaceutical marketing. Acad Med. 2004;79:1046–1050
  30. Allman RL. The relationship between physicians and the pharmaceutical industry: ethical problems with the every day conflict of interest. HEC Forum. 2003;15:155–170
  31. Bellin M, McCarthy S, Drevlow L, Pierach C. Medical students' exposure to pharmaceutical industry marketing: a survey at one U.S. medical school. Acad Med. 2004;79:1041–1045
  32. Brennan TA, Mello MM. Sunshine laws and the pharmaceutical industry. JAMA. 2007;297:1255–1257
  33. Brennan TA, Rothman DJ, Blank L, et al. Health industry practices that create conflicts of interest: a policy proposal for academic medical centers. JAMA. 2006;295:429–433
  34. Brett AS, Burr W, Moloo J. Are gifts from pharmaceutical companies ethically problematic? (A survey of physicians). Arch Intern Med. 2003;163:2213–2218
  35. Campbell EG, Gruen RL, Mountford J, Miller LG, Cleary PD, Blumenthal D. A national survey of physician-industry relationships. N Engl J Med. 2007;356:1742–1750
  36. Dana J, Loewenstein G. A social science perspective on gifts to physicians from industry. JAMA. 2003;290:252–255
  37. Dresser R. Pharmaceutical company gifts: from voluntary standards to legal demands. Hastings Cent Rep. 2006;36:8–9
  38. Elliott C. Pharma goes to the laundry: public relations and the business of medical education. Hastings Cent Rep. 2004;34:18–23
  39. Fugh-Berman A. PharmedOut. 2008. http://www.pharmedout.org/industry.htmAccessed: February 25, 2008
  40. Silverman E. Pharmalot: Star-Ledger of New Jersey, 2008. http://www.pharmalot.comAccessed: April 1, 2008
  41. Rutledge P, Crookes D, McKinstry B, Maxwell SR. Do doctors rely on pharmaceutical industry funding to attend conferences and do they perceive that this creates a bias in their drug selection? Results from a questionnaire survey. Pharmacoepidemiol Drug Safety. 2003;12:663–667
  42. Goldratt E, Cox J. The goal: a process of ongoing improvement. 3rd ed.. Great Barrington, Massachusetts: North River Press; 2004;
  43. Isaacson B, Silk A, Philip Morris. Marlboro Friday. HBS No. 9–596–001. Harvard Business Online. Boston, Massachusetts: Harvard Business School Publishing, 1997. http://harvardbusinessonline.hbsp.harvard.edu/Accessed: March 26, 2008
  44. Kachra A, Crossan M. Starbucks. IVEY No. 98M006. Harvard Business Online. London, Ontario, Canada: Richard Ivey School of Business, 1997. http://harvardbusinessonline.hbsp.harvard.eduAccessed: March 26, 2008
  45. Quan SF. Doctor, do you have a minute? (The dilemma posed by physician interaction with the pharmaceutical industry). J Clin Sleep Med. 2007;3:345–346
  46. Stossel T. Regulation of financial conflicts of interest in medical practice and medical research: a damaging solution in search of a problem. Perspect Biol Med. 2007;50:54–71
  47. Ferguson J. My $100,000 sideline. Medical Economics. 2004 November 19. http://medicaleconomics.modernmedicine.com/memag/Clinical+Pharmacology/My-100000-sideline/ArticleStandard/Article/detail/133888Accessed: April 1, 2008
  48. Pharmaceutical Research and Manufacturers of America. PhRMA code on interactions with healthcare professionals, 2004. Revised. http://www.phrma.org/files/2004-01-19.391.pdfAccessed: April 1, 2008
  49. American Medical Association. Updated clarification on opinion E-8.061: gifts to physicians from industry, 1998. http://www.ama-assn.org/ama/pub/category/8484.htmlAccessed: April 1, 2008
  50. Popp RL SSJ, Adams RJ, Antman EM, et al. American Heart Association (ACCF/AHA consensus conference report on professionalism and ethics). Circulation. 2004;110:2506–2549
  51. Romano M. AMA forges ahead (Unveiling of educational campaign paid by drug industry triggers new criticism). Mod Healthc. 2001;31:22–23
  52. Tonelli MR. Conflict of interest in clinical practice. Chest. 2007;132:664–670
  53. Sieghart P. Professions as the conscience of society. J Med Ethics. 1985;11:117–122
  54. Mather C. The pipeline and the porcupine: alternate metaphors of the physician-industry relationship. Soc Sci Med. 2005;60:1323–1334
  55. Chren M. Interactions between physicians and drug company representatives. Am J Med. 1999;107:182–183
  56. Steinman M, Bero LA, Chren M-M, Landefeld CS. The promotion of gabapentin: an analysis of internal industry documents. Ann Int Med. 2006;145:284–293
  57. Maslow A. A theory of human motivation. Psychol Rev. 1943;50:370–396
  58. Hayashi J. Free meals from the pharmaceutical industry. JAMA. 2001;285:164–165author reply 165–166
  59. Sierles F, Brodkey AC, Cleary LM, et al. Medical students' exposure to and attitudes about drug company interactions. JAMA. 2005;294:1034–1042
  60. Steinman M, Shlipak MG, McPhee SJ. Of principles and pens: attitudes of medical house staff toward pharmaceutical company promotions. Am J Med. 2001;110:551–557
  61. Greene JA. Pharmaceutical marketing research and the prescribing physician. Ann Intern Med. 2007;146:742–748
  62. Pharma Marketing Network. Key opinion leader. 2004. http://dx.doi.org/10.1371/journal.pmed.005001Accessed: April 1, 2008
  63. Gagnon M, Lexchin J. The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States. PLoS.Med 2008;5:e1. http://dx.doi.org/10.1371/journal.pmed.0050001Accessed: April 1, 2008
  64. Orlowski J, Wateska L. The effects of pharmaceutical firm enticements on physician prescribing patterns: there's no such thing as a free lunch. Chest. 1992;102:270–273
  65. Oldani M. Thick prescriptions: toward an interpretation of pharmaceutical sales practices. Med Anthro Q. 2004;18:325–356
  66. ACCME. Annual Report, 2006. http://www.accme.org/dir_docs/doc_upload/f51ed7d8-e3b4-479a-a9d8-57b6efedc27a_uploaddocument.pdfAccessed: April 1, 2008
  67. Ehringhaus S, Weissman JS, Sears JL, Goold SD, Feibelmann S, Campbell EG. Responses of medical schools to institutional conflicts of interest. JAMA. 2008;299:665–671
  68. Rothman D. Academic medical centers and financial conflicts of interest. JAMA. 2008;299:695–697
  69. Steinbrook R. Guidance for guidelines. N Engl J Med. 2007;356:331–333
  70. Kassirer J. On the take: how medicine's complicity with big business can endanger your health. In: New York, New York: Oxford University Press; 2005;p. 204–205
  71. Coyne D. Influence of industry on renal guideline development. Clin J Am Soc Nephrol. 2007;2:3–7
  72. Kuehn BM. Pharmaceutical industry funding for residencies sparks controversy. JAMA. 2005;293:1572–1580
  73. Healy D. In the grip of the python: conflicts at the university-industry interface. Sci Eng Ethics. 2003;9:59–71
  74. Blumenthal D. Doctors and drug companies. N Engl J Med. 2004;351:1885–1890
  75. Cain D, Loewenstein G, Moore DA. The dirt on coming clean: perverse effects of disclosing conflicts of interest. J Legal Stud. 2005;34:1–25
  76. Camilleri M, Cortese DA. Managing conflict of interest in clinical practice. Mayo Clin Proc. 2007;82:607–614
  77. Harris G. Cigarette company paid for lung cancer study. New York Times, March 26, 2008:A1.
  78. Berenson A. Study reveals doubt on drug for cholesterol. New York Times, January 15, 2008:A1.
  79. Saul S. Group with industry ties backs drug. New York Times, January 24, 2008:C1.
  80. Ross JS, Lackner JE, Lurie P, Gross CP, Wolfe S, Krumholz HM. Pharmaceutical company payments to physicians: early experiences with disclosure laws in Vermont and Minnesota. JAMA. 2007;297:1216–1223
  81. United States Senate Special Committee on Aging. Grassley, Kohl say public should know when pharmaceutical makers give money to doctors. Press release. September 7, 2007. http://aging.senate.gov/record.cfm?id=282004Accessed: April 1, 2008
  82. Chimonas S, Rothman DJ. New federal guidelines for physician-pharmaceutical industry relations: the politics of policy formation. Health Affairs. 2005;24:949–960
  83. The Pew Charitable Trusts. The prescription project: advancing medical practice and policy, 2007. http://www.pewtrusts.org/our_work.aspx?category=206Accessed: April 1, 2008
  84. McCarthy M. US campaign tackles drug company influence over doctors. Lancet. 2007;369:730
  85. The Prescription Project, 2007. http://www.prescriptionproject.org/about/Accessed: April 1, 2008
  86. Krasner J. Mass. group links drug costs, marketing. The Boston Globe, January 17, 2008:2D.
  87. Fletcher S. Chairman's summary of the conference. In:  Hager M editors. Continuing education in the health professions: improving healthcare through lifelong learning, 2008. November 28 to December 1, 2007. Bermuda, New York: Josiah Macy, Jr. Foundation; 2008;
  88. Newswire, U.S.. Thousands of medical students urge schools to eliminate pharmaceutical marketing influence. National pharmfree week commences today. October 22, 2007. http://findarticles.com/p/articles/mi_hb5554/is_200710/ai_n21917439Accessed: April 1, 2008
  89. Moses H, Braunwald E, Martin JB, Thier SO. Collaborating with industry—choices for the academic medical center. N Engl J Med. 2002;347:1371–1375
  90. Millard WB. Docking the tail that wags the dog: banning drug reps from academic medical facilities. Ann Emerg Med. 2007;49:785–791
  91. Kassirer JP. Commercialism and medicine: an overview. Camb Q Health Ethics. 2007;16:377–386discussion 439–442
  92. Katz D, Caplan AL, Merz JF. All gifts large and small: toward an understanding of the ethics of pharmaceutical industry gift-giving. Am J Bioeth. 2003;3:39–46
  93. Kennedy JF. Yale University commencement address. June 11, 1962. http://www.jfklibrary.org/Historical+Resources/Archives/Reference+Desk/Speeches/JFK/003POF03Yale06111962.htmAccessed: April 1, 2008

PII: S0002-9394(08)00276-6

doi: 10.1016/j.ajo.2008.04.007

American Journal of Ophthalmology
Volume 146, Issue 2 , Pages 159-171 , August 2008

Article Tools